- |||||||||| Journal: American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy. (Pubmed Central) - Jan 5, 2018
In carefully selected patients, a combination of systemic treatment and SABR may offer long-term PFS. The current guidelines have been created to provide clinicians with a review of the data supporting BT in the management of STS as well as providing indications and technique guidelines to ensure optimal patient selection and clinical outcomes.
- |||||||||| zidovudine / Generic mfg., Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Review, Journal: Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. (Pubmed Central) - Jan 5, 2018 Experimental approaches to treatment include virus activated cytotoxic therapy with high-dose zidovudine and valganciclovir and targeting human interleukin-6 activity. Despite successful treatment of KSHV-MCD, patients remain at high risk for developing non-Hodgkin lymphomas.
- |||||||||| AMG 337 / ImmunityBio, Amgen
Enrollment open, Trial initiation date, Metastases: QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma (clinicaltrials.gov) - Jan 5, 2018 P2, N=10, Recruiting, Despite successful treatment of KSHV-MCD, patients remain at high risk for developing non-Hodgkin lymphomas. Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Jan 2018
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial termination, Trial primary completion date, Metastases: Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung (clinicaltrials.gov) - Jan 5, 2018 P2, N=12, Terminated, Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Jan 2018 N=35 --> 12 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Oct 2016; low accrual
- |||||||||| Review, Journal: The promise of signal transduction in genetically driven sarcomas of the nerve. (Pubmed Central) - Jan 3, 2018
Taking advantage of the rapid development of novel therapeutics targeting key molecular pathways across all cancer types, the best-in-class modulators of these pathways can be assessed in pre-clinical models and translated into clinical trials for patients with MPNST. Here, we describe the genetic changes and molecular pathways that drive MPNST formation and highlight the promise of signal transduction to identify therapies that may treat these tumors more effectively.
- |||||||||| Review, Journal: Consensus and controversies regarding the treatment of rhabdomyosarcoma. (Pubmed Central) - Jan 3, 2018
Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) - Jan 3, 2018 P2, N=37, Recruiting, Our proposed multimodal strategy apparently meets the aggressive biologic nature of NMC and should be considered for further evaluation in this context potentially in the setting of a clinical trial. Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2019 --> Sep 2019
- |||||||||| Preclinical, Journal: Pacifastin-derived Peptides Target Tumors for Use in In Vivo Imaging. (Pubmed Central) - Jan 2, 2018
Our studies demonstrate the potential utility of mocetinostat combined with gemcitabine for the treatment of LMS. Although there are some obstacles to developing pacifastin-derived peptides for therapeutic activity, these optimized peptides have great promise for cancer imaging.
- |||||||||| Visudyne (verteporfin) / Novartis
Journal: TAZ and YAP are frequently activated oncoproteins in sarcomas. (Pubmed Central) - Dec 31, 2017 Knock-down of TAZ and YAP demonstrate differential activity for the two proteins. Verteporfin decreases colony formation in soft agar as well as CTGF expression in sarcoma cell lines harboring activated TAZ and YAP.
- |||||||||| Review, Journal: Title: Re-calculating! Navigating through the osteosarcoma treatment roadblock. (Pubmed Central) - Dec 30, 2017
Additionally, increased understanding of the genetics, signaling pathways and microenvironmental factors driving the disease has led to the identification of promising agents and potential paths towards translation of an exciting array of novel targeted therapies. Here, we review the mechanism of action of these emerging therapies and how, with clinical translation, they can potentially improve the survival rates for osteosarcoma patients in the near future.
- |||||||||| Clinical, Journal: Proton therapy for pediatric head and neck malignancies. (Pubmed Central) - Dec 29, 2017
PBT appears safe for this patient population, with local control rates similar to historical reports. Longer follow-up will be required to evaluate late toxicity and long-term disease control.
- |||||||||| cisplatin / Generic mfg.
Review, Journal: Current and future therapeutic approaches for osteosarcoma. (Pubmed Central) - Dec 28, 2017 Several phase II studies are ongoing or in development that offer hope based on intriguing preclinical data. Furthermore, initiatives in obtaining specimens to further explore the genetic and immunological profile behind osteosarcoma will be essential towards identifying novel pathways and targets to exploit.
- |||||||||| Preclinical, Journal: Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. (Pubmed Central) - Dec 27, 2017
Dependency on GPX4 was found to exist across diverse therapy-resistant states characterized by high expression of ZEB1, including epithelial-mesenchymal transition in epithelial-derived carcinomas, TGFβ-mediated therapy-resistance in melanoma, treatment-induced neuroendocrine transdifferentiation in prostate cancer, and sarcomas, which are fixed in a mesenchymal state owing to their cells of origin. We identify vulnerability to ferroptic cell death induced by inhibition of a lipid peroxidase pathway as a feature of therapy-resistant cancer cells across diverse mesenchymal cell-state contexts.
- |||||||||| Trial completion, Trial primary completion date: A Pilot RCT of the PRISM Intervention for AYAs With Cancer (clinicaltrials.gov) - Dec 27, 2017
P2, N=100, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2017 --> Nov 2017
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), epacadostat (INCB024360) / Incyte
Enrollment open, Trial initiation date, Stroma, Metastases: Epacadostat and Pembrolizumab in Patients With GIST (clinicaltrials.gov) - Dec 26, 2017 P2, N=23, Recruiting, Trial primary completion date: May 2017 --> Jun 2019 Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> Jan 2018
|